Achieve, Disc, and Revolution Among Recipients of First FDA National Priority Vouchers
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 17 2025
0mins
Should l Buy REGN?
Source: SeekingAlpha
FDA Priority Review Vouchers: Achieve Life Sciences, Disc Medicine, and Revolution Medicines are among the first recipients of the FDA's National Priority Review vouchers, aimed at expediting the review process for important medicines, reducing timelines from 10-12 months to 1-2 months.
Market Reactions: Following the announcement, Achieve Life Sciences and Disc Medicine saw significant premarket gains of approximately 25% and 20%, respectively, while Revolution Medicines increased by about 9% due to its pancreatic cancer therapy receiving a voucher.
Other Recipients: Other pharmaceutical companies, including Regeneron, Sanofi, and EMD Serono, also received priority review vouchers, with EMD Serono's fertility treatment Pergoveris highlighted by President Trump for its potential to lower costs in the market.
Program Goals: The FDA's pilot program is designed to encourage the development of drugs that address significant national priorities, such as unmet medical needs and domestic drug manufacturing.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy REGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on REGN
Wall Street analysts forecast REGN stock price to rise
22 Analyst Rating
16 Buy
6 Hold
0 Sell
Moderate Buy
Current: 787.500
Low
637.00
Averages
808.50
High
1057
Current: 787.500
Low
637.00
Averages
808.50
High
1057
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
REGENERON ANTICIPATES PRICING OBESITY DRUG COMPETITIVELY WITH NON-CHOLESTEROL-LOWERING THERAPIES - TD COWEN CONFERENCE
Regeneron Drug Expectations: Regeneron anticipates that its obesity drug will be priced competitively, aligning closely with existing therapies in the market.
Comparison with Other Therapies: The new drug is expected to offer similar benefits to current treatments that do not provide cholesterol-lowering effects.
See More
Biotech Giants Poised for Growth in 2026
- Regeneron Growth Drivers: Regeneron Pharmaceuticals has seen a 34% increase in sales of Dupixent and a 66% rise in Eylea HD, indicating strong market demand for its treatments of inflammatory and retinal diseases, which is expected to further drive earnings growth.
- Rich Product Pipeline: With numerous late-stage programs in hematology, immunology, and rare diseases, Regeneron is well-positioned for future growth, even if only a few products reach commercialization, enhancing its investment appeal.
- Vertex Market Leadership: Vertex Pharmaceuticals' CFTR modulators can treat 90% of cystic fibrosis patients, and the company is developing new candidates to address those not benefiting from existing products, ensuring its leadership position in the market.
- Revenue Diversification Expansion: Vertex's CF drugs generate billions in revenue, and with recent approvals for new treatments like Casgevy and Journavx, the company is poised for significant revenue growth in the coming years.
See More
Biotech Giants Offer Growth and Safety
- Strong Sales Growth: Regeneron Pharmaceuticals reported a 34% increase in global sales of Dupixent and a 66% rise in U.S. sales of Eylea HD in the recent quarter, indicating robust market demand for treatments of inflammatory and retinal diseases, which is expected to drive future revenue growth.
- Rich Product Pipeline: With multiple late-stage programs in hematology, immunology, and rare diseases, Regeneron's potential growth points will support future performance, even if only a few products reach commercialization.
- Market Leadership: Vertex Pharmaceuticals leads the cystic fibrosis treatment market with its CFTR modulators, which can treat 90% of patients, and is developing new candidates to address unmet needs, ensuring sustained market share growth.
- Diversified Revenue Sources: Vertex's CF drugs generate billions in annual revenue, and the company's expansion into gene editing and non-opioid pain treatments will provide strong momentum for future revenue growth.
See More
Latest Rating Changes on Wall Street
- Semiconductor Opportunities: Loop initiates coverage of Astera Labs with a buy rating, highlighting the company's potential across all generative AI silicon solutions that address critical pain points in AI server and cluster experiences, which could enhance its market share.
- Auto Parts Investment Advice: Deutsche Bank upgrades Dauch Corporation from hold to buy, suggesting that investors should seize the opportunity amid recent stock weakness before an acquisition, with expectations that the company's margin targets will be supported going forward.
- Vacation Market Outlook: Mizuho upgrades Marriott Vacations from market perform to outperform, raising the price target from $58 to $104, indicating a 52% upside potential that reflects strong prospects in the vacation market.
- Insurance Sector Dynamics: Goldman Sachs upgrades AIG from neutral to buy, citing strong earnings growth potential, particularly as AIG's improving return on equity stands out amidst peers facing decelerating earnings growth due to cyclical pressures.
See More
Chronic Kidney Disease Market Growth Drivers
- Market Size Growth: According to analysis, the chronic kidney disease (CKD) market size was approximately $4.8 billion in 2024 and is expected to grow further by 2034, reflecting increased demand for new therapies and an expanding patient base.
- Rising Patient Numbers: In 2024, there were about 82 million prevalent cases of CKD across the 7 major markets (7MM), with projections indicating continued growth from 2025 to 2034, primarily driven by an aging population and the rising prevalence of diabetes and hypertension.
- Launch of New Therapies: The introduction of emerging therapies such as AstraZeneca's Zibotentan/Dapagliflozin and Boehringer Ingelheim's Vicadrostat + Empagliflozin is expected to significantly boost market growth and improve treatment outcomes for patients.
- Advancements in Biomarkers: Progress in biomarkers like KIM-1 and NGAL enables more precise early detection of CKD, thereby enhancing the potential for timely interventions and improving overall patient prognosis.
See More
EMA Recommends Dupixent Approval for Children with Chronic Urticaria
- Pediatric Indication Expansion: The European Medicines Agency's Committee recommends approval of Sanofi and Regeneron's Dupixent (dupilumab) for treating chronic spontaneous urticaria in children aged 2 to 11, marking a significant expansion in the drug's pediatric indications, which is expected to substantially boost market demand and sales.
- Clinical Trial Support: This recommendation is supported by data from the phase 3 LIBERTY-CUPID program, demonstrating Dupixent's efficacy against chronic spontaneous urticaria, further solidifying its position in the treatment landscape and likely attracting more prescriptions from healthcare providers.
- Existing Approval Status: Dupixent is already approved for chronic spontaneous urticaria in individuals aged 12 and older, and the expansion into pediatric indications will enable it to capture a larger share of the competitive market, enhancing the companies' influence in the pediatric pharmaceutical sector.
- Optimistic Market Outlook: With the application of Dupixent in the pediatric population, it is anticipated to drive long-term growth for both Sanofi and Regeneron, especially against the backdrop of rising demand for allergy-related medications, thereby further enhancing their competitiveness in the pharmaceutical industry.
See More
REGENERON ANTICIPATES PRICING OBESITY DRUG COMPETITIVELY WITH NON-CHOLESTEROL-LOWERING THERAPIES - TD COWEN CONFERENCE
Regeneron Drug Expectations: Regeneron anticipates that its obesity drug will be priced competitively, aligning closely with existing therapies in the market.
Comparison with Other Therapies: The new drug is expected to offer similar benefits to current treatments that do not provide cholesterol-lowering effects.
See More
Biotech Giants Poised for Growth in 2026
- Regeneron Growth Drivers: Regeneron Pharmaceuticals has seen a 34% increase in sales of Dupixent and a 66% rise in Eylea HD, indicating strong market demand for its treatments of inflammatory and retinal diseases, which is expected to further drive earnings growth.
- Rich Product Pipeline: With numerous late-stage programs in hematology, immunology, and rare diseases, Regeneron is well-positioned for future growth, even if only a few products reach commercialization, enhancing its investment appeal.
- Vertex Market Leadership: Vertex Pharmaceuticals' CFTR modulators can treat 90% of cystic fibrosis patients, and the company is developing new candidates to address those not benefiting from existing products, ensuring its leadership position in the market.
- Revenue Diversification Expansion: Vertex's CF drugs generate billions in revenue, and with recent approvals for new treatments like Casgevy and Journavx, the company is poised for significant revenue growth in the coming years.
See More
Biotech Giants Offer Growth and Safety
- Strong Sales Growth: Regeneron Pharmaceuticals reported a 34% increase in global sales of Dupixent and a 66% rise in U.S. sales of Eylea HD in the recent quarter, indicating robust market demand for treatments of inflammatory and retinal diseases, which is expected to drive future revenue growth.
- Rich Product Pipeline: With multiple late-stage programs in hematology, immunology, and rare diseases, Regeneron's potential growth points will support future performance, even if only a few products reach commercialization.
- Market Leadership: Vertex Pharmaceuticals leads the cystic fibrosis treatment market with its CFTR modulators, which can treat 90% of patients, and is developing new candidates to address unmet needs, ensuring sustained market share growth.
- Diversified Revenue Sources: Vertex's CF drugs generate billions in annual revenue, and the company's expansion into gene editing and non-opioid pain treatments will provide strong momentum for future revenue growth.
See More
Latest Rating Changes on Wall Street
- Semiconductor Opportunities: Loop initiates coverage of Astera Labs with a buy rating, highlighting the company's potential across all generative AI silicon solutions that address critical pain points in AI server and cluster experiences, which could enhance its market share.
- Auto Parts Investment Advice: Deutsche Bank upgrades Dauch Corporation from hold to buy, suggesting that investors should seize the opportunity amid recent stock weakness before an acquisition, with expectations that the company's margin targets will be supported going forward.
- Vacation Market Outlook: Mizuho upgrades Marriott Vacations from market perform to outperform, raising the price target from $58 to $104, indicating a 52% upside potential that reflects strong prospects in the vacation market.
- Insurance Sector Dynamics: Goldman Sachs upgrades AIG from neutral to buy, citing strong earnings growth potential, particularly as AIG's improving return on equity stands out amidst peers facing decelerating earnings growth due to cyclical pressures.
See More
Chronic Kidney Disease Market Growth Drivers
- Market Size Growth: According to analysis, the chronic kidney disease (CKD) market size was approximately $4.8 billion in 2024 and is expected to grow further by 2034, reflecting increased demand for new therapies and an expanding patient base.
- Rising Patient Numbers: In 2024, there were about 82 million prevalent cases of CKD across the 7 major markets (7MM), with projections indicating continued growth from 2025 to 2034, primarily driven by an aging population and the rising prevalence of diabetes and hypertension.
- Launch of New Therapies: The introduction of emerging therapies such as AstraZeneca's Zibotentan/Dapagliflozin and Boehringer Ingelheim's Vicadrostat + Empagliflozin is expected to significantly boost market growth and improve treatment outcomes for patients.
- Advancements in Biomarkers: Progress in biomarkers like KIM-1 and NGAL enables more precise early detection of CKD, thereby enhancing the potential for timely interventions and improving overall patient prognosis.
See More
EMA Recommends Dupixent Approval for Children with Chronic Urticaria
- Pediatric Indication Expansion: The European Medicines Agency's Committee recommends approval of Sanofi and Regeneron's Dupixent (dupilumab) for treating chronic spontaneous urticaria in children aged 2 to 11, marking a significant expansion in the drug's pediatric indications, which is expected to substantially boost market demand and sales.
- Clinical Trial Support: This recommendation is supported by data from the phase 3 LIBERTY-CUPID program, demonstrating Dupixent's efficacy against chronic spontaneous urticaria, further solidifying its position in the treatment landscape and likely attracting more prescriptions from healthcare providers.
- Existing Approval Status: Dupixent is already approved for chronic spontaneous urticaria in individuals aged 12 and older, and the expansion into pediatric indications will enable it to capture a larger share of the competitive market, enhancing the companies' influence in the pediatric pharmaceutical sector.
- Optimistic Market Outlook: With the application of Dupixent in the pediatric population, it is anticipated to drive long-term growth for both Sanofi and Regeneron, especially against the backdrop of rising demand for allergy-related medications, thereby further enhancing their competitiveness in the pharmaceutical industry.
See More
